coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Athena PCN, Maidstone · Health Inequalities Profile

    PCN U92100 · NHS Kent and Medway Integrated Care Board · 1 GP practice

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    25,738

    Registered population

    56.8% aged 18–64

    22.1%

    Aged 65+

    ICB 19.9% · England 17.9%

    6.6%

    Ethnic minority (non-White)

    2.4% Asian · England 9.6%

    0.4%

    In IMD quintile 1

    ICB 17.1% · England 21.0%

    ~100

    Core20 residents (est.)

    Resident basis; registered basis ~108 · see page 3

    4,325

    Hypertension register

    +8.43% in 3 yrs · England +5.60%

    181

    SMI register

    10.7% of Maidstone's

    466

    COPD register

    Reviews -41.97% in 3 yrs

    Forecast to 2030

    5,526

    Hypertension patients, 2030

    +1,201 on today

    54.6%

    QRISK ≥20% on statins, 2030

    -0.12pp over 3 yrs

    7.2%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    45.3%
    Asthma annual review coverage trails benchmarks.

    Asthma review coverage is 45.3% (Maidstone 63.2%, ICB 60.4%, England 65.7%), after a -25.1% three-year change, leaving about 880 patients without a recorded review.

    -12.5 pp
    Childhood MMR uptake below 95% target.

    In Q1 2025/26, 24-month MMR dose 1 coverage is 82.5% (12.5 pp below the 95% target), with an 8.6 pp age-five first-to-second-dose gap.

    75.4%
    Breast and cervical screening exceed England.

    Breast screening coverage (ages 53 to 70) is 75.4% (England 69.9%) and cervical screening (ages 25-49) is 73.0% (England 66.8%), outperforming Maidstone and ICB.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Athena PCN serves an older population, with 22.1% aged 65 and over

    Athena PCN serves 25,738 registered patients through Greensand Medical Group. Patients aged 65 and over make up 22.1% (5,694 people), exceeding Maidstone (18.7%), NHS Kent and Medway ICB (19.9%) and England (17.9%), alongside unverified projected list growth of 7.6% to 2030 (England 2.3%). Patients aged 0-17 comprise 21.1% and aged 18-64 represent 56.8%. Based on Census usual-resident estimates in associated areas rather than practice registrations, 93.4% identify as White (Maidstone 89.8%, ICB 88.6%, England 81.1%), with a 6.6% non-White share and 0.8% identifying as Gypsy or Irish Traveller (Maidstone 0.6%, ICB 0.3%, England 0.1%).

    Age profile

    0–1721.1%
    18–6456.8%
    65+22.1%

    65+: ICB 19.9%, England 17.9%

    Ethnicity

    White93.4%
    Asian2.4%
    Mixed2.0%
    Black1.5%
    Other0.8%

    Older people · falls rows are Maidstone local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Maidstone LA)2,6532,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)73.8%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)51.1%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Maidstone LA)1,3809819552024/25
    Falls deaths, all ages, per 100,000 (Maidstone LA)15.814.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Athena PCN records an average IMD decile of 5.7 and 0.4% Core20 share

    Athena PCN records an average IMD decile of 5.7 (Maidstone 5.9, ICB 5.4, England 5.5). Its Core20 share is 0.4% (Maidstone 9.9%, ICB 17.1%, England 21.0%), with 0 associated decile 1 or 2 LSOAs. Resident Core20 count is estimated at about 100, while Greensand Medical Group's registered share yields 108 patients. Low area deprivation may mask pocket need, consistent with register growth in depression (+27.6% vs England +7.7%) and learning disability (+30.4% vs England +5.4%), which clinical audit would test.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Greensand Medical0.4% · 108 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    181

    SMI register

    0.70% recorded prevalence

    195

    Learning disability register

    0.76% recorded prevalence

    7

    Care homes, 219 beds

    In the PCN catchment

    8.7%

    Provide unpaid care

    Maidstone, Census 2021

    The PCN records 195 patients with learning disabilities (0.8% prevalence, above Maidstone at 0.6%, ICB at 0.6%, and England at 0.6%) and 181 on the severe mental illness register (0.7%, below Maidstone at 0.9%, ICB at 0.9%, and England at 1.0%). Catchment infrastructure includes 7 care homes with 219 beds. Lower recorded SMI prevalence than England (0.7% vs 1.0%) does not establish under-detection; clinical register audit would test diagnostic capture.

    Severe mental illness: physical health checks

    Recorded SMI prevalence is 0.7% (England 1.0%). Annual BMI recording fell 3.2 pp over 2023 to 2025 (England +5.1 pp) to 72.3% (England 82.1%), whereas blood pressure checks reached 81.3% (England 83.4%). Metabolic monitoring requires targeted recall.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    4,325

    Hypertension register

    +8.43%

    Register growth, 3 yrs

    Maidstone +4.31% · England +5.60%

    −5.16pp

    BP control, under 80

    ≤140/90 · −9.83pp aged 80+

    +1,201

    More patients by 2030

    Forecast 5,526 (19.81%)

    Hypertension case-finding and control

    Hypertension prevalence is 16.8% (4,325 patients), above Maidstone (16.0%), the ICB (16.2%) and England (15.2%). While 89.5% have a recent blood pressure check (England 90.0%), blood pressure control is 60.7% in under-80s (England 67.8%, falling 7.8% over 2023 to 2025 versus England +3.2%) and 69.1% in those aged 80+ (England 81.2%, falling 12.5% versus England +2.2%). Blood pressure control lags comparators most markedly in older cohorts, indicating an operational priority to intensify clinical review and medication titration.

    Lipids and statins

    Among patients with QRISK ≥ 20%, 54.9% receive lipid-lowering therapy (England 63.6%, Maidstone 60.3%), down 0.2% over 2023 to 2025 (England +6.2%). In chronic kidney disease, lipid therapy is 65.4% (England 70.3%, ICB 69.2%). Fewer at-risk patients receive lipid-lowering therapy than England benchmarks, indicating an area for proactive recall.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202637,913£1.70£1.90£1.86£64,452
    Cardiovascular (all), 202550,536£2.98£3.57£3.33£150,597

    In 2026, 37,913 lipid-regulating items were prescribed at £1.70 per item (£64,452 annual spend), compared to £1.86 in England and £1.62 in Maidstone. Across these items, the PCN spent £6,066 less than at England's unit cost. Unit cost is a cost indicator rather than an efficiency measure, without establishing case-mix or treatment coverage.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −25.07%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −2.13%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 6.7% (1,608 patients), but 12-month reviews fell 25.1% over 2023 to 2025 (England +4.4%) to 45.3% (England 65.7%, Maidstone 63.2%, ICB 60.4%), leaving about 880 patients without a recorded review. COPD prevalence is 1.8% (466 patients), with annual reviews falling 42.0% over 2023 to 2025 (England +2.8%) to 47.4% (England 76.4%, Maidstone 70.6%, ICB 72.5%). Sharp falls could reflect review capacity bottlenecks, unverified locally, which clinical audit would test.

    Cancer register and children's immunisation

    Recorded cancer prevalence is 5.4% (1,379 patients; England 3.8%). In Q1 2025/26, 24-month MMR1 coverage is 82.5% (England 88.3%, ICB 89.4%). At age 5, MMR1 reaches 93.8% (England 91.7%) while MMR2 is 85.2% (an 8.6 pp gap), and 4-in-1 booster coverage is 84.0%. Lower second-dose and booster completion may reflect recall attrition, unverified locally, which audit would test.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months91.4%

    England 91.0%

    6-in-1 complete primary course at 24 months88.9%

    England 92.2%

    MMR dose 1 at 24 months82.5%

    England 88.3%

    MMR dose 2 at age 585.2%

    England 82.8%

    4-in-1 pre-school booster at age 584.0%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Kent and Medway ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,630

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Kent and Medway ICBEnglandNo usable stageStaged cancers
    Breast82.1%85.4%23%1,509
    Prostate54.4%53.2%37%1,435
    Lung29.4%33.8%21%1,109
    Bowel48.2%47.0%29%1,013
    Skin cancer87.5%87.8%23%562

    In 2022, 55.6% of staged cancers in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384 staged cases; England 55.3%), up 2.2 pp since 2013 but 19.4 pp below the 75.0% national ambition by 2028. Known-stage completeness was 63.6% (8,384 of 13,189 registrations; England 67.0%), requiring about 1,630 extra early-stage diagnoses annually across the ICB. System figures reflect wider pathways rather than PCN performance; locally, ATHENA PCN cancer prevalence is 5.4% (1,379 patients; 3-year change +16.1% vs England +9.0%), with breast screening at 75.4% (England 69.9%) and cervical screening at 73.0% (England 66.8%).

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026 (provisional), Maidstone and Tunbridge Wells NHS Trust achieved 87.4% on 62-day referral to treatment (standard 85.0%; ICB 75.9%, England 71.2%), 81.8% on the 28-day faster diagnosis standard (standard 75.0%; ICB 76.8%, England 79.3%), and 98.3% on 31-day combined treatment (standard 96.0%; ICB 95.8%, England 92.5%). In diagnostics, 6.4% of patients waited 6+ weeks across all tests (England 23.1%), with colonoscopy at 19.8% (England 30.8%) and flexi sigmoidoscopy at 28.2% (England 32.1%). Provider and trust measures describe secondary care activity rather than PCN performance.

    Pathways within standard (%)Maidstone and Tunbridge WellsMedwayDartford and GraveshamKent and Medway ICBEngland
    28-day faster diagnosis (75%)81.7877.7778.1476.7879.32
    31-day treatment (96%)98.3599.6297.4895.8492.50
    62-day referral to treatment (85%)87.4381.6463.5975.9371.16
    Diagnostic waits over 6 weeks (%)Maidstone and Tunbridge WellsMedwayDartford and GraveshamEngland
    MRI0.920.680.3621.40
    CT0.510.002.089.92
    Echocardiography2.5736.623.9028.48
    Colonoscopy19.801.880.4030.83
    Gastroscopy24.033.320.0029.02
    All 15 DM01 tests6.4214.208.3723.14
    Community services activityKent residentsKent and Medway ICB
    Care contacts210,170254,055
    Referrals59,36068,085
    Patients with a contact60,60572,060

    Community services (residents of Kent), Jun 2026 (provisional). In June 2026 (provisional), Kent residents had 210,170 community care contacts across 60,605 patients, with 138,250 contacts (65.8%) among adults aged 65+ and 31,385 among children aged 0-18. Across NHS Kent and Medway Integrated Care Board, 72,060 patients recorded 254,055 contacts (165,655 aged 65+). These provisional experimental figures describe county and ICB activity rather than PCN-specific caseloads.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Greensand Medical Group recorded 46.9% good patient experience alongside 100.0% clinical QOF achievement

    In 2025/26, Greensand Medical Group attained 100.0% in QOF clinical achievement (England 97.1%) and 90.8% overall (England 92.5%). However, vaccination and immunisation achievement reached 18.9% (England 55.2%), while personalised care adjustments across all domains were 12.4% (England 10.0%).

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Greensand Medical1770.420.9%59.7%46.9%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNMaidstoneAssetPCNMaidstone
    Care homes (catchment)7 (219 beds)n/aSchools (catchment)36n/a
    Children's centres17Places of worship2994
    Libraries29Food banks (VCS)n/a1
    Homelessness support (VCS)n/a1Day centres (VCS)13
    Children and young people (VCS)n/a3Carers support groups (VCS)14
    Primary schools (LA maintained)828Primary academies614

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    Asthma 12-month review completion is 45.3% of the 1,608 register (Maidstone 63.2%, ICB 60.4%, England 65.7%), leaving about 880 patients without a recorded review. For discussion, Greensand Medical Group could run a single-template asthma recall alongside repeat inhaler prescribing checks and flexible review slots. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension and high-risk lipid recall

    On the 4,325 hypertension register, BP control is 69.1% in ages 80+ (England 81.2%) and 60.7% in under-80s (England 67.8%); QRISK >= 20% lipid therapy is 54.9% (England 63.6%). For discussion, the PCN could establish pharmacist-led recall and home BP monitoring titration for uncontrolled hypertension and untreated high-QRISK patients. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Childhood MMR and booster recall

    In Q1 2025/26, 24-month MMR1 is 82.5% (12.5 pp below the 95.0% target; England 88.3%), age-5 4-in-1 is 84.0%, and age-5 MMR2 (85.2%) trails MMR1 (93.8%) by 8.6 pp. For discussion, Greensand Medical Group could audit children missing 24-month MMR1 and age-5 boosters and offer catch-up clinic slots. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Inclusion health outreach (p2)Gypsy or Irish TravellerNeighbourhood health framework · Core20PLUS5 approachPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Physical health check recall (p4)SMI register with a BMI recorded in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension blood pressure control review (p5)Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Childhood booster recall audit (p6)MMR dose 1 coverage at 24 months10YHP sickness to prevention · 95% targetPCN
    Suspected cancer pathway safety netting (p7)Cancers diagnosed at stage 1 or 2 (All cancer sites)—ICB
    Telephony and appointment access review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Hypertension and high-risk lipid recall (p12)Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Childhood MMR and booster recall (p12)MMR dose 1 coverage at 24 months · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15